Endomedix
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Endomedix - overview
Established
2005
Location
Newark, NJ, US
Primary Industry
Medical Devices & Equipment
About
Endomedix is a specialized medical technology company focused on PLEXimine™, a precision polysaccharide chemistry platform that enhances biosurgery and various medical applications. Endomedix, founded in 2005 in Newark, US, develops innovative medical solutions aimed at improving surgical outcomes. The company has successfully completed 2 deals, with its most recent funding round occurring on April 22, 2024, raising USD 500,000 from Central Texas Angel Network. The founders are John Abrahams and Piyush M, while Richard Russo serves as CEO.
Endomedix operates independently without known subsidiaries or parent companies. Endomedix specializes in PLEXimine™, a technology based on precision polysaccharide chemistry designed to enhance biosurgery and various medical applications. This innovative platform allows surgeons to create dynamic, structured medical devices in situ, significantly improving surgical outcomes. PLEXimine™ caters to established and emerging surgical procedures, bridging gaps in current technologies.
The primary customers include hospitals and surgical centers across North America, Europe, and select regions in Asia, where advanced surgical techniques are increasingly adopted. Endomedix generates revenue primarily through direct sales of PLEXimine™ to healthcare institutions, utilizing a B2B partnership model with hospitals and surgical facilities. This structured approach likely includes bulk purchasing agreements, ensuring a consistent supply of their proprietary technology. Revenue is derived from transactions as healthcare entities integrate PLEXimine™ into their offerings, with pricing reflective of enhanced patient outcomes and procedural effectiveness.
The company aims to build long-term relationships with clients to reinforce its presence in the biosurgery market. In April 2024, Endomedix raised USD 500,000 in venture funding from Central Texas Angel Network, which will be utilized to accelerate the development and commercialization of PlexiClot. The company plans to bring this transformative technology to healthcare providers and patients worldwide, focusing on expanding its market presence.
Current Investors
Central Texas Angel Network
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment, Biomaterials
Website
www.endomedix.com
Total Amount Raised
Subscriber access only
Endomedix - employee data
Endomedix - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President & Chief Executive Officer, Board member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.